FDA Approves Vectibix in mCRC Along with KRAS Diagnostic

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved the Amgen agent Vectibix (panitumumab) for use in combination with FOLFOX as first-line treatment in patients with wild-type KRAS (exon 2) metastatic colorectal cancer.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login